DK1398369T3 - Bifidobacterium longum-bakterier og præparater indeholdende disse - Google Patents

Bifidobacterium longum-bakterier og præparater indeholdende disse

Info

Publication number
DK1398369T3
DK1398369T3 DK03013441T DK03013441T DK1398369T3 DK 1398369 T3 DK1398369 T3 DK 1398369T3 DK 03013441 T DK03013441 T DK 03013441T DK 03013441 T DK03013441 T DK 03013441T DK 1398369 T3 DK1398369 T3 DK 1398369T3
Authority
DK
Denmark
Prior art keywords
bifidobacterium longum
preparations containing
strain
pure culture
biologically pure
Prior art date
Application number
DK03013441T
Other languages
English (en)
Inventor
Giuseppe Claudio Viscomi
Leone Gabriele Rotini
Lorenzo Morelli
Patrizio Ferrari
Maria Rosaria Pantaleo
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Application granted granted Critical
Publication of DK1398369T3 publication Critical patent/DK1398369T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/02—Making cheese curd
    • A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
    • A23C19/0323—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin using only lactic acid bacteria, e.g. Pediococcus and Leuconostoc species; Bifidobacteria; Microbial starters in general
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
    • A23C19/061—Addition of, or treatment with, microorganisms
    • A23C19/062—Addition of, or treatment with, microorganisms using only lactic acid bacteria, e.g. pediococcus, leconostoc or bifidus sp., or propionic acid bacteria; Treatment with non-specified acidifying bacterial cultures
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK03013441T 2002-09-06 2003-06-23 Bifidobacterium longum-bakterier og præparater indeholdende disse DK1398369T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000564A ITBO20020564A1 (it) 2002-09-06 2002-09-06 Bifidobatteri e preparazioni che li contengono.

Publications (1)

Publication Number Publication Date
DK1398369T3 true DK1398369T3 (da) 2006-10-23

Family

ID=31726535

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05011028T DK1609852T3 (da) 2002-09-06 2003-06-23 Bifidobakterier og præparater indeholdende disse
DK03013441T DK1398369T3 (da) 2002-09-06 2003-06-23 Bifidobacterium longum-bakterier og præparater indeholdende disse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK05011028T DK1609852T3 (da) 2002-09-06 2003-06-23 Bifidobakterier og præparater indeholdende disse

Country Status (13)

Country Link
US (1) US6960341B2 (da)
EP (2) EP1609852B1 (da)
JP (1) JP4011532B2 (da)
KR (1) KR100574455B1 (da)
CN (1) CN100386427C (da)
AT (2) ATE376053T1 (da)
CA (1) CA2436752C (da)
DE (2) DE60316995T2 (da)
DK (2) DK1609852T3 (da)
ES (2) ES2293419T3 (da)
IT (1) ITBO20020564A1 (da)
PT (2) PT1609852E (da)
SI (2) SI1398369T1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7029702B2 (en) * 1998-07-07 2006-04-18 Ritter Natural Sciences Llc Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
US10066254B2 (en) 2002-05-20 2018-09-04 Cedars-Sinai Medical Center Diagnosis of constipation by analysis of methane concentration
ES2535489T3 (es) 2002-05-20 2015-05-12 Cedars-Sinai Medical Center Diagnóstico del estreñimiento por análisis de la concentración de metano
WO2005017095A2 (en) * 2003-08-18 2005-02-24 The Bio Balance Corporation A stable liquid probiotic composition, preparation and applications thereof
WO2006012536A2 (en) * 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
US20100233312A9 (en) * 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
CA2647161A1 (en) 2006-05-28 2007-12-06 Cipla Medpro Research And Development (Pty) Ltd Probiotic strain and antimicrobial peptide derived therefrom
MY146590A (en) * 2007-03-28 2012-08-30 Alimentary Health Ltd Probiotic bifidobacterium strains
PL2266582T3 (pl) * 2008-03-18 2015-10-30 Dikovskiy Aleksander Vladimirovich Mieszanka farmaceutyczna do zapobiegania dysbiozie związanej z enteralnym podawaniem antybiotyków
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US20110189148A1 (en) * 2008-06-25 2011-08-04 Ritter Pharmaceuticals, Inc. Lactose compositions with decreased lactose content
ES2331863B1 (es) * 2008-07-15 2010-10-27 Consejo Superior De Investigaciones Cientificas (Csic) Bacterias y productos derivados para fortalecer las defensas y reducir el riesgo de enfermedad.
KR101017448B1 (ko) * 2008-09-18 2011-02-23 주식회사한국야쿠르트 대장의 건강 증진 효능을 갖는 비피도박테리움 롱검 에이취와이8004 및 이를 유효성분으로 함유하는 제품
CN107320480A (zh) 2009-02-24 2017-11-07 里特制药股份有限公司 益生素制剂和使用方法
CN101649303B (zh) * 2009-05-08 2011-09-28 内蒙古蒙牛乳业（集团）股份有限公司 一种双歧杆菌及其应用和含有双歧杆菌的食品组合物
JP5860396B2 (ja) * 2009-05-11 2016-02-16 ネステク ソシエテ アノニム ラクトバチルス・ジョンソニーＬａ１ＮＣＣ５３３（ＣＮＣＭＩ−１２２５）及び免疫障害
EP2270134A1 (en) * 2009-07-03 2011-01-05 Nestec S.A. Oxidative stress resistant Bifidobacteria
WO2011137249A1 (en) 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
RU2470518C1 (ru) * 2011-05-27 2012-12-27 Закрытое акционерное общество "АЛЕВ" Молочный йогурт с пробиотическими культурами
WO2013130773A2 (en) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
CN111494375A (zh) 2013-03-15 2020-08-07 雪松-西奈医学中心 由产甲烷菌引起或与之相关的疾病和病状的诊断、选择和治疗方法
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
CN104095180A (zh) * 2013-04-12 2014-10-15 中国科学院烟台海岸带研究所 一种益生菌菊粉片及其制备方法
GB2535034A (en) 2013-07-21 2016-08-10 Whole Biome Inc Methods and systems for microbiome characterization, monitoring and treatment
CA2955666A1 (en) 2014-08-13 2016-02-18 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
CN113730442A (zh) 2014-10-31 2021-12-03 潘德勒姆治疗公司 与病症的微生物治疗和诊断有关的方法和组合物
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
KR20180006378A (ko) * 2015-04-30 2018-01-17 프로바이오티컬 에스.피.에이. 특이적인 치료학적 활성을 가진 항생제를, 동일한 치료학적 적응증과 비-전이성 항생제 내성을 가진 락토바실러스 및/또는 비피도박테리움의 동시 사용과 조합하는 병용 방법
US20180228179A1 (en) * 2015-06-08 2018-08-16 Chr. Hansen A/S Glycerin-based gummy candy and foam candy products with probiotic bacteria
CN105112333A (zh) * 2015-08-31 2015-12-02 江南大学 一种具有良好肠道定殖能力的长双歧杆菌及筛选方法和应用
DK3554283T3 (da) * 2016-12-14 2020-11-16 Chr Hansen As Glycerin- og proteinbaserede skumslikprodukter med probiotiske bakterier
BR112019015792A8 (pt) * 2017-01-31 2023-01-03 Univ Kansas State Células microbianas, métodos de sua produção e usos destas
CN106978340B (zh) * 2017-06-04 2018-01-30 合肥职业技术学院 一种双歧杆菌专用培养装置
CA3073838A1 (en) 2017-08-30 2019-03-07 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
CN110438042A (zh) * 2019-07-23 2019-11-12 广东益可维健康科技有限公司 一株长双歧杆菌及其应用
KR102607676B1 (ko) * 2019-12-04 2023-11-29 선 바이오 (주) 내산소성 비피도박테리움 균주를 유효성분으로 포함하는 반려동물용 생균제 조성물 및 이의 제조방법
CN112353823A (zh) * 2020-12-16 2021-02-12 梁爱军 一种能在胃肠同时发挥作用的益生菌液
CN112715660A (zh) * 2021-01-18 2021-04-30 润盈生物工程（上海）有限公司 一种干预慢性肾炎及尿毒症的长双歧杆菌膳食组合及应用
CN115474695B (zh) * 2021-05-31 2024-01-19 仙乐健康科技股份有限公司 一种调节宿主肠道微生物平衡的制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69219768T2 (de) * 1992-07-06 1997-08-28 Nestle Sa Milchbakterien
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US6306638B1 (en) * 1996-10-22 2001-10-23 Food Industry Research And Development Institute Mutant bifidobacteria strains with acid, bile salt and oxygen tolerance
DE69600525T2 (de) * 1996-12-23 1998-12-10 Sitia Yomo Spa Lyophilisierte, lebende Bakerien enthaltende Nahrungszusammensetzung
EP0931543B1 (de) * 1997-12-19 2002-03-20 MERCK PATENT GmbH Mehrschichttablette enthaltend probiotische Mikroorganismen wie z.B. Lactobacilli oder Bifidobakterien
WO1999033854A1 (en) 1997-12-26 1999-07-08 Research Development Foundation Mammalian circadian regulator m-rigui2 (m-per2)
EP1107691A4 (en) 1998-08-24 2005-04-06 Martin C Baruch APPARATUS AND METHOD FOR MEASURING PULSE TRANSIT TIME
NL1010770C2 (nl) * 1998-12-09 2000-06-13 Nutricia Nv Preparaat dat oligosacchariden en probiotica bevat.
DK1353681T3 (da) * 1999-08-05 2008-03-10 Nestle Sa Bifidobakterier i stand til at modvirke diarré

Also Published As

Publication number Publication date
CN1480528A (zh) 2004-03-10
JP4011532B2 (ja) 2007-11-21
DE60307191T2 (de) 2007-07-26
SI1398369T1 (sl) 2006-12-31
DK1609852T3 (da) 2007-12-27
JP2004097222A (ja) 2004-04-02
US6960341B2 (en) 2005-11-01
EP1609852B1 (en) 2007-10-17
ES2268226T3 (es) 2007-03-16
PT1609852E (pt) 2008-01-25
PT1398369E (pt) 2006-12-29
ATE376053T1 (de) 2007-11-15
CA2436752C (en) 2010-02-02
CA2436752A1 (en) 2004-03-06
ATE335071T1 (de) 2006-08-15
ES2293419T3 (es) 2008-03-16
SI1609852T1 (sl) 2008-02-29
KR20040022386A (ko) 2004-03-12
EP1609852A1 (en) 2005-12-28
EP1398369A1 (en) 2004-03-17
EP1398369B1 (en) 2006-08-02
DE60307191D1 (de) 2006-09-14
DE60316995T2 (de) 2008-07-24
ITBO20020564A1 (it) 2004-03-07
US20040047850A1 (en) 2004-03-11
CN100386427C (zh) 2008-05-07
KR100574455B1 (ko) 2006-04-27
DE60316995D1 (de) 2007-11-29

Similar Documents

Publication Publication Date Title
DK1398369T3 (da) Bifidobacterium longum-bakterier og præparater indeholdende disse
Culligan et al. Metagenomics and novel gene discovery: promise and potential for novel therapeutics
Ehrlich et al. The distributed genome hypothesis as a rubric for understanding evolution in situ during chronic bacterial biofilm infectious processes
NO20051651L (no) Naeringspreparater inneholdende synbiotiske forbindelser
PE20010829A1 (es) Alimento para mascotas destinado al tratamiento de la especie helicobacter en las mascotas
CN108367030A (zh) 普氏粪杆菌和惰性脱硫弧菌用于治疗或预防糖尿病和肠病
US10653728B2 (en) Probiotic compositions for improving metabolism and immunity
Ahire et al. Survival and germination of Bacillus clausii UBBC07 spores in in vitro human gastrointestinal tract simulation model and evaluation of clausin production
EA017558B1 (ru) ШТАММ БАКТЕРИЙ Е.Mundtii ST4SA, СПОСОБНЫЙ ПРОДУЦИРОВАТЬ АНТИБАКТЕРИАЛЬНЫЙ ПЕПТИД ST4SA, СПОСОБ ПОЛУЧЕНИЯ ПЕПТИДА ST4SA И ПРИМЕНЕНИЕ ШТАММА БАКТЕРИЙ Е.Mundtii ST4SA И ПЕПТИДА
Macfarlane, MJ Hopkins, GT Macfarlane Bacterial growth and metabolism on surfaces in the large intestine
EP2834377A1 (en) Lactobacillus rhamnosus food grade bacteria
CN110475853A (zh) 新颖乳酸菌及其应用
Schimmel et al. Breast milk urea as a nitrogen source for urease positive Bifidobacterium infantis
Bai et al. Recent progress in experimental and human disease-associated multi-species biofilms
Gati et al. Comparative phenotypic characterization of hybrid Shiga toxin-producing/uropathogenic Escherichia coli, canonical uropathogenic and Shiga toxin-producing Escherichia coli
Effendi et al. Prospective and challenges of live bacterial therapeutics from a superhero Escherichia coli Nissle 1917
CN107208044A (zh) 被工程化为治疗与高氨血症相关的疾病的细菌
Hemmis et al. Thioredoxin-like proteins in F and other plasmid systems
Kelley et al. Metal homeostasis in pathogenic Epsilonproteobacteria: mechanisms of acquisition, efflux, and regulation
Lin et al. DsbL and DsbI contribute to periplasmic disulfide bond formation in Salmonella enterica serovar Typhimurium
Raj et al. Genomic and metabolic properties of Staphylococcus gallinarum FCW1 MCC4687 isolated from naturally fermented coconut water towards GRAS assessment
Balaganesh et al. Probiotic curd as antibacterial agent against pathogens causing oral deformities–in vitro microbiological study
Almuzara et al. Isolation of Bordetella species from unusual infection sites
Bhattarai et al. Next-generation microbial drugs developed from microbiome's natural products
Olsvik et al. Production of enterotoxin by Escherichia coli at four, twenty-two and thirty-seven degrees centigrade